Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87456706 | 8745670 | 6 | F | 20160825 | 20120826 | 20160826 | EXP | GB-BRISTOL-MYERS SQUIBB COMPANY-16898553 | BRISTOL MYERS SQUIBB | 0.00 | F | Y | 0.00000 | 20160826 | CN | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87456706 | 8745670 | 1 | PS | SUSTIVA | EFAVIRENZ | 1 | Transplacental | 400 MG, QD | U | 20972 | 400 | MG | CAPSULE | QD | |||||
| 87456706 | 8745670 | 2 | SS | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Transplacental | UNK UNK, QD | U | 0 | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 87456706 | 8745670 | 1 | Product used for unknown indication |
| 87456706 | 8745670 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 87456706 | 8745670 | OT |
| 87456706 | 8745670 | CA |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 87456706 | 8745670 | Foetal exposure during pregnancy | |
| 87456706 | 8745670 | Turner's syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 87456706 | 8745670 | 1 | 2011 | 0 | ||
| 87456706 | 8745670 | 2 | 2011 | 0 |